Registered title, quoted from ClinicalTrials.gov
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07105579, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
14 years to 65 years; sex: all
Registered eligibility fields
ECOG performance status <3 and Karnofsky score ≥70.
Inclusion criterion 6
Pregnant or lactating women, or women of childbearing potential unwilling to use effective contraception.
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07105579, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 14-65 years (inclusive), regardless of gender.
- Newly diagnosed B-ALL with CD19 expression on leukemic cells (regardless of CD19 positivity rate).
- Ph-negative B-ALL with high-risk features post-allo-HSCT .
- ≥2 months post-transplant with hematopoietic reconstitution.
- Bone marrow morphology in remission and MRD-negative before enrollment.
- ECOG performance status <3 and Karnofsky score ≥70.
- No history of grade III/IV graft-versus-host disease (GVHD) and no active GVHD at enrollment.
- Adequate organ function:AST and ALT ≤3× upper limit of normal (ULN), total bilirubin ≤2×ULN.Serum creatinine ≤2×ULN or creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula).Left ventricular ejection fraction (LVEF) ≥50% by echocardiography (ECHO).
- Expected survival >3 months.
- Voluntary provision of written informed consent, with ability to understand and comply with study requirements.
Exclusion Criteria:
- History of hypersensitivity or severe adverse reactions to the study drug or structurally similar compounds, as assessed by the investigator to preclude participation.
- Pregnant or lactating women, or women of childbearing potential unwilling to use effective contraception.
- Severe cardiac dysfunction, including:Left ventricular ejection fraction (EF) <60%.Clinically significant arrhythmias (e.g., ventricular tachycardia, atrial fibrillation, second-degree heart block).Prolonged QTc interval (men >450 ms; women >470 ms).Myocardial infarction within the past year.Symptomatic coronary artery disease requiring medication.
- Severe pulmonary dysfunction (obstructive and/or restrictive ventilatory impairment).
- Severe hepatic impairment:ALT or total bilirubin (TBIL) >3× upper limit of normal (ULN).
- Severe renal impairment:Serum creatinine (Cr) >2× ULN.24-hour creatinine clearance (Ccr) <50 mL/min.
- Active infection or uncontrolled bleeding, as assessed by the investigator to preclude safe administration of the study drug.
- History of thrombosis, embolism, cerebral hemorrhage, or other significant vascular events within the past year.
- Psychiatric disorders or other conditions that impair the ability to provide informed consent or comply with study procedures.
- Major organ surgery within the past six weeks.
- Drug abuse or chronic alcoholism that may interfere with study assessments.
- Prior organ transplantation (excluding hematopoietic stem cell transplantation).
- Other conditions deemed by the investigator to make the patient unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07105579, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07105579, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.